Product Approvals, Delays, & Disappointments
The PharmaTell team had Eyes on new products this week – watching Lilly’s Mounjaro approval, UBS’s Bimzelx CRL, and Roche’s SKYSCRAPER-1 data.
Home »
Robin Bateman
Quarterly Results, Biogen, & Conference Planning
The PharmaTell Team has been busy this week curating Quarterly Results Reports & upcoming conference planners + keeping up with Biogen next steps.
AACR Updates & CAR-T Overview
This week the team has been enjoying the Spring Holidays, Reviewing the AACR Highlights, and Learning about CAR-T.
Patient Volumes Recovering + Aduhelm
This week we had Eyes on Patient Volumes – post-COVID recovery + the CMS Final say on Aduhelm Coverage.
PharmaTell Studio Upgrades
This week we want to share the latest upgrades to PharmaTell Studio. As always we are innovating to help you keep your eyes on you & your competition.
FDA Approvals, Transcripts, & Conferences
This week the team has been looking at congress planners, transcripts, and the US FDA.
Gene Therapy Guidance
This week the team had Eyes on Gene Editing – well some new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.
Industry Intel
This week the team had Eyes on Intel – Biotech Industry Intel that is. With over 100K reports in the database we know some of the more strategic – global reports can be overlooked.
Tracking data
The Eyes on Pharma team took a wander through the database to look for tracking data…
Opioids, SPACs, Top 10 Lists, and of course More Results
This week the Eyes on Pharma team was, like you, reviewing all of the results & guidance news – whew! But we still found a few other topics trending we thought you might be interested in. Check out the latest on some of the Opioid Litigation, SPACS, and yes two Top 10 Lists! See below for the tidbits from the week ending 20 Feb.